Onyx' potential blockbuster for multiple myeloma Kyprolis wins early US FDA approval
This article was originally published in Scrip
Multiple myeloma patients who may have run out of hope have a new treatment option that may add months to their lives now that the US FDA has granted accelerated approval to Onyx Pharmaceuticals' intravenous product Kyprolis (carfilzomib), which could become a blockbuster drug.
You may also be interested in...
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.